Pharmaceutical Processing

West Pharmaceutical Services (NYSE:WST) announced the opening of a new facility for contract services in Dublin, Ireland. IDA Ireland, the foreign direct investment arm for the Irish government, shared the announcement of the Damastown site’s opening. The 165,000-square-foot expansion enhances West’s contract services. It helps meet the growing demand for high-volume treatments, including for diabetes…

Thermo Fisher Scientific today announced a strategic collaboration with drug delivery system provider SHL Medical. The collaboration coincides with the expansion of sterile fill-finish and auto-injector final assembly capacity at its Ridgefield, New Jersey site. Together, Thermo Fisher says its investments establish a fully integrated U.S.-based offering across sterile manufacturing, device assembly and commercial packaging…

Wilmington PharmaTech announced a $50 million investment to expand its Delaware campus for active pharmaceutical ingredient (API) manufacturing. Newark, Delaware-based Wilmington PharmaTech said the expansion more than doubles its current API reactor capacity. It adds two new 10,000-liter reactor suites to increase commercial-scale manufacturing capabilities. This supports growing demand for high-quality, U.S.-based manufacturing as the…

Cambrex announced today that it achieved multiple milestones in its effort to expand its active pharmaceutical ingredient (API) manufacturing. East Rutherford, New Jersey-based Cambrex said it completed the initial engineering studies for a new, large-scale API manufacturing plant in Charles City, Iowa. It also added further investment to support its Milan, Italy, site. The latest…

Plastic Ingenuity announced today that it’s expanding its operations into Europe with the acquisition of Spezi-Pack. Located near Dresden, Germany, Spezi-Pack is an established thermoforming company. Madison, Wisconsin-based Plastic Ingenuity said the expansion enables it to offer regional European manufacturing for medical device and pharmaceutical packaging. The acquisition helps to increase efficiencies along the value…

BioDuro announced that it established a joint venture with Cenra API Solutions, also known as Chunghwa Chemical Synthesis & Biotech Co. The joint venture aims to combine the services of the CRDMO and a pharmaceutical chemical manufacturer. They hope to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra’s campus in Taipei, Taiwan, to…

Novo Nordisk today announced plans to invest €432 million ($507 million) in its facility in Monksland, Athlone, Ireland. The Danish pharmaceutical giant plans to add significant additional manufacturing capacity for current and future GLP-1 treatments. According to Novo Nordisk, the expansion of the tabletting facility further reinforces its long-term commitment to Ireland and global healthcare…

Novartis announced today that it plans to establish a new radioligand therapy (RLT) manufacturing site in Denton, Texas. The purpose-built RLT site will mark Novartis’ fifth in the U.S. and first manufacturing facility in Texas. It comes as part of a planned $23 billion investment across the U.S. Novartis has, in the past couple of…

Bora Pharmaceuticals and GSK announced today that they entered into a $250 million agreement to renew a five-year manufacturing partnership. In 2020, Bora purchased a facility in Mississauga, Ontario, from GSK. Now, they say the renewed collaboration reinforces their long-standing relationship and expands their partnership. It also provides GSK access to multiple sites within the…

AbbVie (NYSE:ABBV) today announced plans to invest $380 million in two new active pharmaceutical ingredient (API) manufacturing facilities. The investment comes at the company’s current North Chicago, Illinois, campus. With it, the company plans to add new, state-of-the-art facilities to integrate advanced manufacturing technologies with AI to support the production of its next-generation neuroscience and…